A Prospective Observational Study of Adoptive Immunotherapy for Cancer using Autologous Activated Lymphocytes

A Prospective Observational Study of Adoptive Immunotherapy for Cancer using Autologous Activated Lymphocytes - AIT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000021797

Enrollment

Registered

2016-04-06

Start date

2017-03-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable or recurrent cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically-defined panreatic cancer 2) Measurable lesion 3) un-treated 4) Age 20-80 5) PS 0-2 6) Estimated prognosis >= 3 months 7) Sufficient organ function WBC>4,000/mm3, <12,000/mm3 NE>2,000/mm3 PLT>100.000/mm3 Hg>10.0g/dl GOT/GPT<Normal range x 2 Bil<1.5mg/dl Creat<1.5mg/dl 8) Written informed consent 9) No pregnancy

Exclusion criteria

Exclusion criteria: 1) Autoimmune disease 2) Uncontrollable complications including infection, diabetes, hypertension, ischemic heart disease, cerebral infarction, interstitial pneumonitis, cancer pain 3) Pregnancy 4) Allergy 5) General symptoms including dyspnea, jaundice, edema, effusions, clamp, paralysis, fracture, difficult for out-patient 6) Double cancer 7) Other cancer treatment 8) Steroid or immunosuppressive agents 9) Other unacceptable reasons

Design outcomes

Primary

Measure	Time frame
Overall Survival	—

Countries

Japan

Contacts

Public ContactYAMAGUCHI Yoshiyuki

Kawasaki Medical School Department of Clinical Oncology

shogo@med.kawasaki-m.ac.jp086-462-1111

Outcome results